The TG Therapeutics Inc. (TGTX) Rating Reiterated by Roth Capital

The TG Therapeutics Inc. (TGTX) Rating Reiterated by Roth Capital

TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by investment analysts at Roth Capital in a research report issued on Friday. They currently have a $33.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price objective would indicate a potential upside of 449.08% from the stock’s current price.

TGTX has been the topic of several other research reports. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Monday, September 19th. S&P Equity Research reduced their price target on shares of TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. Brean Capital reaffirmed a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a report on Thursday, October 6th. Finally, Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $21.21.

TG Therapeutics (NASDAQ:TGTX) opened at 6.01 on Friday. TG Therapeutics has a 12 month low of $5.41 and a 12 month high of $14.87. The firm has a 50-day moving average of $7.38 and a 200 day moving average of $7.33. The stock’s market cap is $327.28 million.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%. Analysts anticipate that TG Therapeutics will post ($1.22) EPS for the current year.

Institutional investors have recently modified their holdings of the company. Bridger Management LLC bought a new position in shares of TG Therapeutics during the first quarter valued at approximately $28,503,000. Pictet Asset Management Ltd. raised its position in shares of TG Therapeutics by 753.5% in the second quarter. Pictet Asset Management Ltd. now owns 1,215,449 shares of the biopharmaceutical company’s stock valued at $9,140,000 after buying an additional 1,073,049 shares during the period. UBS Asset Management Americas Inc. raised its position in shares of TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock valued at $17,223,000 after buying an additional 466,193 shares during the period. Vanguard Group Inc. raised its position in shares of TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock valued at $8,995,000 after buying an additional 152,700 shares during the period. Finally, Opaleye Management Inc. raised its position in shares of TG Therapeutics by 38.3% in the first quarter. Opaleye Management Inc. now owns 415,000 shares of the biopharmaceutical company’s stock valued at $3,536,000 after buying an additional 115,000 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

Related posts

Leave a Comment